Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tg Therapeutics (NQ: TGTX )

23.53 -0.22 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,413,587
Open 23.75
Bid (Size) 23.50 (1)
Ask (Size) 23.66 (1)
Prev. Close 23.75
Today's Range 22.52 - 24.01
52wk Range 6.460 - 25.70
Shares Outstanding 154,420,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why NASDAQ:TGTX is Poised for High Growth.
Exploring TG THERAPEUTICS INC (NASDAQ:TGTX)'s growth characteristics. 
Via Chartmill

Performance

YTD
+38.09%
+38.09%
1 Month
+13.95%
+13.95%
3 Month
+47.99%
+47.99%
6 Month
+43.74%
+43.74%
1 Year
+121.56%
+121.56%

More News

Read More
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Via Chartmill
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Decoding TG Therapeutics's Options Activity: What's the Big Picture?
Via Benzinga
Why the growth investor may take a look at NASDAQ:TGTX.
Via Chartmill
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga
NASDAQ:TGTX: a strong growth stock preparing for the next leg up?.
Via Chartmill
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
Via Investor's Business Daily
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill
$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
(TGTX) - Analyzing TG Therapeutics's Short Interest
Via Benzinga
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
TGTX Stock Earnings: TG Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%
Via Investor's Business Daily
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Via Chartmill
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Via The Motley Fool
Nasdaq 100 Overbought? Here’s What History Says About The Current Rally
Via Talk Markets
The Most Shorted Stocks in June: Hold, Short, or Squeeze?
Via MarketBeat
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Via FinancialNewsMedia
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.